Modality
ERT
MOA
EGFRi
Target
FXIa
Pathway
Amyloid
ALLCF
Development Pipeline
Preclinical
Mar 2018
→ Feb 2029
PreclinicalCurrent
NCT03799718
2,400 pts·ALL
2018-03→2025-04·Active
NCT07287544
1,371 pts·ALL
2025-09→2029-02·Terminated
3,771 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-04-2111mo agoInterim· ALL
2029-02-242.9y awayInterim· ALL
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
Preclinical
Active
Preclinical
Termina…
Catalysts
Interim
2025-04-21 · 11mo ago
ALL
Interim
2029-02-24 · 2.9y away
ALL
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03799718 | Preclinical | ALL | Active | 2400 | OS |
| NCT07287544 | Preclinical | ALL | Terminated | 1371 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa |